On September 29, 2026 UTR Therapeutics Inc., a biotech company with clinical trial-ready assets defining a new category of RNA therapeutics to conquer the undruggable proteome, reported that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to 3′UTRMYCN M1-14 (UTRxMYCN M1-14) for the treatment of soft tissue sarcoma, including rhabdomyosarcoma (RMS), and Rare Pediatric Disease Designation (RPDD) for the treatment of rhabdomyosarcoma.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The company’s core technology of ultra-targeted 3′UTR engineering, invented by Chidiebere U. Awah, M.D., Ph.D. (CEO, UTR Therapeutics Inc.), targets the oncogenic mRNA of undruggable genes, overwrites their endogenous oncogenic mRNA messages, and triggers them for degradation by the nonsense-mediated decay pathway, thus eliminating the diseased mRNA while sparing the healthy mRNA.
MYCN (N-MYC) is a basic helix-loop-helix transcription factor belonging to the MYC superfamily. It is an intrinsically disordered transcription factor with no binding pocket, which has rendered it "undruggable" and beyond the reach of conventional methods. MYCN is a defining oncogenic driver of aggressive soft tissue sarcomas, including fusion-positive rhabdomyosarcoma, the most common soft tissue sarcoma in children. MYCN contributes to a subset of the more than 80 soft tissue sarcoma subtypes affecting children and adults. There are currently no clinically approved therapies that directly target MYCN.
In preclinical studies, UTRxMYCN M1-14, invented by Dr. Awah at UTR Therapeutics Inc., reliably targeted and degraded the oncogenic MYCN in aggressive MYCN-driven rhabdomyosarcoma, including the deadly fusion-positive rhabdomyosarcoma. The drug achieved on-target specificity and therapeutic efficacy, demonstrating dose-dependent inhibition of MYCN, tumor inhibition, and inhibition of liver and lung metastasis while remaining safe.
"The ODD and RPDD designations granted to UTRxMYCN M1-14 by the U.S. FDA validate the UTR Therapeutics platform technology and the potential of UTRxMYCN M1-14 to address several aggressive sarcomas that represent serious unmet needs in the U.S. and worldwide," said David T. Asuzu, M.D., Chief Medical Officer.
About Orphan Drug Designation and Rare Pediatric Disease Designation
The FDA grants Orphan Drug Designation to drugs and biologics intended to treat diseases affecting fewer than 200,000 people in the United States. ODD provides seven years of U.S. market exclusivity upon approval, a tax credit for qualified clinical testing costs, and an exemption from prescription drug user fees.
The FDA grants Rare Pediatric Disease Designation to drugs for serious or life-threatening diseases that primarily affect individuals under 18. RPDD is a prerequisite for a Rare Pediatric Disease Priority Review Voucher, which may be awarded upon FDA approval of the asset, subject to the FDA’s eligibility criteria at the time of approval. The Priority Review Voucher has been recorded to trade at values beyond $195M
(Press release, UTR Therapeutics, SEP 29, 2026, View Source [SID1234671160])